Figure 12. Immunotherapy response and drug sensitivity analysis of IL18RAP. (A) Ability of the IL18RAP to predict OS and response outcomes in cohorts of patients receiving immunotherapy. (B) The TISMO database was used to investigate the predictive power of IL18RAP in mouse immunotherapy cohorts. (C) The TISMO database was used to examine the expression levels of IL18RAP in cell lines that had undergone different treatments. (D) The IL18RAP expression in various datasets obtained from the TIDE platform. (E–G) The effectiveness of IL18RAP as a predictor in response to anti-PD-1 (E), anti-PD-L1 (F), and anti-CTLA4 (G) therapy. (H) The relationship between IL18RAP expression and drug sensitivity of 9 common anticancer drugs.